AR052054A1 - Procesos para la preparacion de derivados del acido 3-fenil-2-arilalquilpropionico - Google Patents
Procesos para la preparacion de derivados del acido 3-fenil-2-arilalquilpropionicoInfo
- Publication number
- AR052054A1 AR052054A1 ARP050105310A ARP050105310A AR052054A1 AR 052054 A1 AR052054 A1 AR 052054A1 AR P050105310 A ARP050105310 A AR P050105310A AR P050105310 A ARP050105310 A AR P050105310A AR 052054 A1 AR052054 A1 AR 052054A1
- Authority
- AR
- Argentina
- Prior art keywords
- processes
- preparation
- arilalquilpropionico
- fenil
- acid derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P11/00—Preparation of sulfur-containing organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
- C12P41/003—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions
- C12P41/005—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions by esterification of carboxylic acid groups in the enantiomers or the inverse reaction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
- C12P7/52—Propionic acid; Butyric acids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se describen procesos enzimáticos y químicos para la preparacion de ciertos derivados de ácido 3-fenil-2-arilalquiltiopropionico que tienen utilidad en el tratamiento de afecciones clínicas que incluyen trastornos lipídicos (dislipidemias), asociados o no con resistencia a insulina, y otras manifestaciones del síndrome metabolico; y además, ciertos nuevos intermediarios utilizados en estos procesos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0427524.4A GB0427524D0 (en) | 2004-12-16 | 2004-12-16 | Chemical process |
Publications (1)
Publication Number | Publication Date |
---|---|
AR052054A1 true AR052054A1 (es) | 2007-02-28 |
Family
ID=34090119
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050105310A AR052054A1 (es) | 2004-12-16 | 2005-12-16 | Procesos para la preparacion de derivados del acido 3-fenil-2-arilalquilpropionico |
Country Status (17)
Country | Link |
---|---|
US (1) | US7803586B2 (es) |
EP (1) | EP1828394A2 (es) |
JP (1) | JP2008523797A (es) |
KR (1) | KR20070094908A (es) |
CN (1) | CN101080495A (es) |
AR (1) | AR052054A1 (es) |
AU (1) | AU2005315454A1 (es) |
BR (1) | BRPI0518948A2 (es) |
CA (1) | CA2588591A1 (es) |
GB (1) | GB0427524D0 (es) |
IL (1) | IL183524A0 (es) |
MX (1) | MX2007007219A (es) |
NO (1) | NO20072633L (es) |
SA (1) | SA05260405A (es) |
TW (1) | TW200636071A (es) |
UY (1) | UY29271A1 (es) |
WO (1) | WO2006064213A2 (es) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001011072A1 (en) | 1999-08-05 | 2001-02-15 | Novo Nordisk A/S | Process for the preparation of substituted 3-phenyl-propanoic acid esters and substituted 3-phenyl-propanoic acids |
JP2003506065A (ja) * | 1999-08-05 | 2003-02-18 | ノボ ノルディスク アクティーゼルスカブ | 置換された3−フェニル−プロパン酸エステル及び置換された3−フェニル−プロパン酸の調製の方法 |
SE0104333D0 (sv) * | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
GB0314130D0 (en) | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
GB0314075D0 (en) | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
GB0314131D0 (en) | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
GB0314260D0 (en) | 2003-06-19 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
-
2004
- 2004-12-16 GB GBGB0427524.4A patent/GB0427524D0/en not_active Ceased
-
2005
- 2005-12-14 MX MX2007007219A patent/MX2007007219A/es not_active Application Discontinuation
- 2005-12-14 CA CA002588591A patent/CA2588591A1/en not_active Abandoned
- 2005-12-14 BR BRPI0518948-9A patent/BRPI0518948A2/pt not_active Application Discontinuation
- 2005-12-14 JP JP2007546171A patent/JP2008523797A/ja active Pending
- 2005-12-14 AU AU2005315454A patent/AU2005315454A1/en not_active Abandoned
- 2005-12-14 EP EP05818266A patent/EP1828394A2/en not_active Withdrawn
- 2005-12-14 SA SA05260405A patent/SA05260405A/ar unknown
- 2005-12-14 US US11/793,134 patent/US7803586B2/en not_active Expired - Fee Related
- 2005-12-14 KR KR1020077015115A patent/KR20070094908A/ko not_active Application Discontinuation
- 2005-12-14 WO PCT/GB2005/004800 patent/WO2006064213A2/en active Application Filing
- 2005-12-14 CN CNA200580043506XA patent/CN101080495A/zh active Pending
- 2005-12-16 TW TW094144603A patent/TW200636071A/zh unknown
- 2005-12-16 AR ARP050105310A patent/AR052054A1/es not_active Application Discontinuation
- 2005-12-20 UY UY29271A patent/UY29271A1/es not_active Application Discontinuation
-
2007
- 2007-05-24 NO NO20072633A patent/NO20072633L/no not_active Application Discontinuation
- 2007-05-29 IL IL183524A patent/IL183524A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2006064213A2 (en) | 2006-06-22 |
TW200636071A (en) | 2006-10-16 |
AU2005315454A1 (en) | 2006-06-22 |
EP1828394A2 (en) | 2007-09-05 |
IL183524A0 (en) | 2007-09-20 |
WO2006064213A3 (en) | 2006-08-24 |
UY29271A1 (es) | 2006-07-31 |
CN101080495A (zh) | 2007-11-28 |
SA05260405A (ar) | 2005-12-03 |
NO20072633L (no) | 2007-06-21 |
BRPI0518948A2 (pt) | 2008-12-16 |
US7803586B2 (en) | 2010-09-28 |
US20080115247A1 (en) | 2008-05-15 |
GB0427524D0 (en) | 2005-01-19 |
MX2007007219A (es) | 2007-08-14 |
CA2588591A1 (en) | 2006-06-22 |
JP2008523797A (ja) | 2008-07-10 |
KR20070094908A (ko) | 2007-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2009000393A1 (es) | Composición farmaceutica que comprende a) un agente farmaceutico activable, b) un agente activo plasmonico; util para el tratamiento de trastornos de proliferación celular. | |
CL2016002589A1 (es) | Uso del compuesto genz-112638 (eliglustat), inhibidor de glucosilceramida sintasa, en el tratamiento de la enfermedad de gaucher y enfermedad de fabry (divisional de solicitud 201201348). | |
CL2017000498A1 (es) | Una formulación de n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforida (galns)(divisional solicitud 219-2013) | |
BRPI0703700A (pt) | nanopartìculas contendo prata com estabilizador de substituição | |
BRPI0514474A (pt) | multiparticulados | |
BR112015019044A2 (pt) | adesivos antimicrobianos tendo proprieda-des aperfeiçoadas | |
WO2010049678A3 (en) | Treatment of energy utilization diseases | |
EA201101189A1 (ru) | Ингибитор sglt-2, предназначенный для лечения сахарного диабета типа 1, сахарного диабета типа 2, нарушенной толерантности к глюкозе или гипергликемии | |
ES2488407T3 (es) | Preparación farmacéutica que contiene lipasa de origen bacteriano | |
UY29086A1 (es) | Nuevas composiciones farmacéuticas para el tratamiento de trastornos hiperproliferativos. | |
UY30931A1 (es) | Amidas de 4-aril-1,4-dihidro-1,6-naftiridina sustituidas y su uso | |
CL2011000301A1 (es) | Compuestos derivados de purina con actividad inmunomoduladora; composición farmacéutica que los comprende; y uso de ellos en el tratamiento de enfermedades alérgicas, rinitis alérgica, asma, enfermedades infecciosas y cáncer. | |
CY1112320T1 (el) | Τιτλοδοτηση της ταπενταδολης | |
UY31543A1 (es) | Sistema de administracion de rnai de interferencia y usos del mismo | |
WO2008057930A3 (en) | Methods of treating neuropathic pain with retinoic acid receptor agonists | |
WO2006073890A3 (en) | Use of glp-1 and agonists thereof to prevent cardiac myocyte apoptosis | |
MX2007011493A (es) | Modalidades antiinflamatorias. | |
PH12014501579A1 (en) | Combination of beta-hydroxy-beta-methylbutyrate, arginine and glutamine for use in treating diabetic ulcers | |
BR112013009660A2 (pt) | proteína de fusão com fator de atividade ix | |
BR112014029721A2 (pt) | sistema de adaptação de palhetas | |
CL2013000709A1 (es) | Composicion que contiene nifurtimox y un antihelmintico seleccionado de: pf1022, emopdepsido, tribendimidina, amidantel, bay d 9216, praziquantel o benzoato de bencilo; util en el tratamiento de enfermedades causadas por giardias (div. sol. 1577-10). | |
DK2175877T3 (da) | Anvendelse af muterede antitrombiner til behandling eller forebyggelse af koagulationssygdomme | |
AR052054A1 (es) | Procesos para la preparacion de derivados del acido 3-fenil-2-arilalquilpropionico | |
TW200503999A (en) | Therapeutic agents | |
NO20071671L (no) | Anvendelse av vintersar (Satureja montana) eller ekstrakter derav for fremstilling av medikamenter til behandling av prematur ejakulering |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |